β2-Adrenergic receptors in immunity and inflammation: Stressing NF-κB

Brain, Behavior, and Immunity

Volumn 45, Issue , 2015, Pages 297-310

  Kolmus, Krzysztof ^a,b   Tavernier, Jan ^a,b   Gerlo, Sarah ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Immunomodulation; Inflammation; NF B; Signalling; Stress; 2 Adrenergic receptor

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN 2; HISTONE H3; I KAPPA B; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; TOLL LIKE RECEPTOR 4; ADRENALIN; NORADRENALIN;

CELL DIFFERENTIATION; CELL MEMBRANE; CELLS BY BODY ANATOMY; DNA BINDING; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; IMMUNOLOGY; MENTAL STRESS;

EPINEPHRINE; HUMANS; INFLAMMATION; NF-KAPPA B; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 84924093305     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.10.007     Document Type: Review

References (118)

1. Ammit A.J., Lazaar A.L., Irani C., O'Neill G.M., Gordon N.D., Amrani Y., Penn R.B., Panettieri R.A. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am. J. Respir. Cell Mol. Biol. 2002, 26:465-474.
2. Baker R.G., Hayden M.S., Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
3. Baouz S., Giron-Michel J., Azzarone B., Giuliani M., Cagnoni F., Olsson S., Testi R., Gabbiani G., Canonica G.W. Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int. Immunol. 2005, 17:1473-1481.
4. Bhatt D., Ghosh S. Regulation of the NF-kappaB-mediated transcription of inflammatory genes. Front. Immunol. 2014, 5:71.
5. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., Ferstl R., von Eynatten M., Wendt T., Rudofsky G., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1920-1925.
6. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav. Immun. 2002, 16:622-653.
7. Bos J.L. Epac: a new cAMP target and new avenues in cAMP research. Nat. Rev. Mol. Cell Biol. 2003, 4:733-738.
8. Bosmann M., Grailer JJ G., Zhu K., Matthay M.A., Sarma J.V., Zetoune F.S., Ward P.A. Anti-inflammatory effects of beta2 adrenergic receptor agonists in experimental acute lung injury. FASEB J. 2012, 26:2137-2144.
9. Bruzzone A., Sauliere A., Finana F., Senard J.M., Luthy I., Gales C. Dosage-dependent regulation of cell proliferation and adhesion through dual beta2-adrenergic receptor/cAMP signals. FASEB J. 2014, 28:1342-1354.
10. Cazzola M., Calzetta L., Matera M.G. Beta(2)-adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 2011, 163:4-17.
11. Chandrasekar B., Marelli-Berg F.M., Tone M., Bysani S., Prabhu S.D., Murray D.R. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem. Biophys. Res. Commun. 2004, 319:304-311.
12. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
13. Chi D.S., Fitzgerald S.M., Pitts S., Cantor K., King E., Lee S.A., Huang S.K., Krishnaswamy G. MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response. BMC Immunol. 2004, 5:22.
14. Chiarella S.E., Soberanes S., Urich D., Morales-Nebreda L., Nigdelioglu R., Green D., Young J.B., Gonzalez A., Rosario C., Misharin A.V., et al. Beta(2)-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. J. Clin. Invest. 2014, 124:2935-2946.
15. Ciccarelli M., Sorriento D., Cipolletta E., Santulli G., Fusco A., Zhou R.H., Eckhart A.D., Peppel K., Koch W.J., Trimarco B., et al. Impaired neoangiogenesis in beta(2)-adrenoceptor gene-deficient mice: restoration by intravascular human beta(2)-adrenoceptor gene transfer and role of NFkappaB and CREB transcription factors. Br. J. Pharmacol. 2011, 162:712-721.
16. Cole S.W., Sood A.K. Molecular pathways: beta-adrenergic signaling in cancer. Clin. Cancer Res. 2012, 18:1201-1206.
17. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
18. De Bosscher K., Vanden Berghe W., Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006, 25:6868-6886.
19. de Montmollin E., Aboab J., Mansart A., Annane D. Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit. Care 2009, 13:230.
20. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
21. Dello Russo C., Boullerne A.I., Gavrilyuk V., Feinstein D.L. Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J. Neuroinflamm. 2004, 1:9.
22. DiDonato J.A., Mercurio F., Karin M. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
23. Djuric Z., Kashif M., Fleming T., Muhammad S., Piel D., von Bauer R., Bea F., Herzig S., Zeier M., Pizzi M., et al. Targeting activation of specific NF-kappaB subunits prevents stress-dependent atherothrombotic gene expression. Mol. Med. 2012, 18:1375-1386.
24. Elenkov I.J., Chrousos G.P. Stress system - organization, physiology and immunoregulation. NeuroImmunoModulation 2006, 13:257-267.
25. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve - an integrative interface between two super systems: the brain and the immune system. Pharmacol. Rev. 2000, 52:595-638.
26. Farmer P., Pugin J. Beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279:L675-L682.
27. Friese R.S., Barber R., McBride D., Bender J., Gentilello L.M. Could beta blockade improve outcome after injury by modulating inflammatory profiles?. J. Trauma 2008, 64:1061-1068.
28. Frost R.A., Nystrom G.J., Lang C.H. Epinephrine stimulates IL-6 expression in skeletal muscle and C2C12 myoblasts: role of c-Jun NH2-terminal kinase and histone deacetylase activity. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E809-17.
29. Gao H., Sun Y., Wu Y., Luan B., Wang Y., Qu B., Pei G. Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol. Cell 2004, 14:303-317.
30. Gao N., Hibi Y., Cueno M., Asamitsu K., Okamoto T. A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling. J. Biol. Chem. 2010, 285:28097-28104.
31. Gavrilyuk V., Dello Russo C., Heneka M.T., Pelligrino D., Weinberg G., Feinstein D.L. Norepinephrine increases I kappa B alpha expression in astrocytes. J. Biol. Chem. 2002, 277:29662-29668.
32. Gavrilyuk V., Horvath P., Weinberg G., Feinstein D.L. A 27-bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells. J. Neurochem. 2001, 78:129-140.
33. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
34. Gloerich M., Bos J.L. Epac: defining a new mechanism for cAMP action. Annu. Rev. Pharmacol. Toxicol. 2010, 50:355-375.
35. Hayden M.S., Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011, 21:223-244.
36. Hayden M.S., Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
37. Herkenham M., Rathore P., Brown P., Listwak S.J. Cautionary notes on the use of NF-kappaB p65 and p50 antibodies for CNS studies. J. Neuroinflamm. 2011, 8:141.
38. Herve J., Dubreil L., Tardif V., Terme M., Pogu S., Anegon I., Rozec B., Gauthier C., Bach J.M., Blancou P. Beta2-Adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells. J. Immunol. 2013, 190:3163-3171.
39. Huang C.H., Chu Y.T., Kuo C.H., Wang W.L., Hua Y.M., Lee M.S., Hung C.H. Effect of procaterol on Th2-related chemokines production in human monocyte and bronchial epithelial cells. Pediatr. Pulmonol. 2010, 45:977-984.
40. Hu Z., Chen R., Cai Z., Yu L., Fei Y., Weng L., Wang J., Ge X., Zhu T., Wang J., Bai C. Salmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells. Cell. Mol. Immunol. 2012, 9:267-275.
41. Jeschke M.G., Gauglitz G.G., Kulp G.A., Finnerty C.C., Williams F.N., Kraft R., Suman O.E., Mlcak R.P., Herndon D.N. Long-term persistence of the pathophysiologic response to severe burn injury. PLoS ONE 2011, 6:e21245.
42. Jeschke M.G., Mlcak R.P., Finnerty C.C., Norbury W.B., Gauglitz G.G., Kulp G.A., Herndon D.N. Burn size determines the inflammatory and hypermetabolic response. Crit. Care 2007, 11:R90.
43. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 2006, 117:18-24. quiz 25.
44. Kato T., Delhase M., Hoffmann A., Karin M. CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol. Cell 2003, 12:829-839.
45. Kaur M., Holden N.S., Wilson S.M., Sukkar M.B., Chung K.F., Barnes P.J., Newton R., Giembycz M.A. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L505-L514.
46. Kim T.K., Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon-beta enhanceosome. Mol. Cell 1997, 1:119-129.
47. Kobilka B.K. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol. Sci. 2011, 32:213-218.
48. Kohm A.P., Mozaffarian A., Sanders V.M. B cell receptor- and beta 2-adrenergic receptor-induced regulation of B7-2 (CD86) expression in B cells. J. Immunol. 2002, 168:6314-6322.
49. Kolmus K., Van Troys M., Van Wesemael K., Ampe C., Haegeman G., Tavernier J., Gerlo S. Beta-agonists selectively modulate proinflammatory gene expression in skeletal muscle cells via non-canonical nuclear crosstalk mechanisms. PLoS ONE 2014, 9:e90649.
50. Kong Y., Ruan L., Qian L., Liu X., Le Y. Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J. Neurosci. 2010, 30:11848-11857.
51. Lam K.P., Chu Y.T., Lee M.S., Chen H.N., Wang W.L., Tok T.S., Chin Y.Y., Chen S.C., Kuo C.H., Hung C.H. Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells. Pediatr. Allergy Immunol. 2011, 22:431-439.
52. Lam K.P., Chu Y.T., Kuo C.H., Wang W.L., Tok T.S., Chin Y.Y., Chen S.C., Hung C.H. Suppressive effects of procaterol on expression of IP-10/CXCL 10 and RANTES/CCL 5 by bronchial epithelial cells. Inflammation 2011, 34:238-246.
53. Laureys G., Gerlo S., Spooren A., Demol F., De Keyser J., Aerts J.L. Beta(2)-adrenergic agonists modulate TNF-alpha induced astrocytic inflammatory gene expression and brain inflammatory cell populations. J. Neuroinflamm. 2014, 11:21.
54. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1:a001651.
55. Lefkowitz R.J., Rajagopal K., Whalen E.J. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol. Cell 2006, 24:643-652.
56. Ley S., Weigert A., Brune B. Neuromediators in inflammation - a macrophage/nerve connection. Immunobiology 2010, 215:674-684.
57. Loop T., Bross T., Humar M., Hoetzel A., Schmidt R., Pahl H.L., Geiger K.K., Pannen B.H. Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. Anesth. Analg. 2004, 99:1508-1515. table of contents.
58. Loza M.J., Foster S., Peters S.P., Penn R.B. Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells. Blood 2006, 107:2052-2060.
59. Luan B., Zhang Z., Wu Y., Kang J., Pei G. Beta-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation. EMBO J. 2005, 24:4237-4246.
60. Ma L., Pei G. Beta-arrestin signaling and regulation of transcription. J. Cell Sci. 2007, 120:213-218.
61. Madrigal J.L., Dello Russo C., Gavrilyuk V., Feinstein D.L. Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid. Redox Signal. 2006, 8:885-892.
62. Mantyh P.W., Rogers S.D., Allen C.J., Catton M.D., Ghilardi J.R., Levin L.A., Maggio J.E., Vigna S.R. Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit, and human. J. Neurosci. 1995, 15:152-164.
63. Maurice P., Guillaume J.L., Benleulmi-Chaachoua A., Daulat A.M., Kamal M., Jockers R. GPCR-interacting proteins major players of GPCR function. Adv. Pharmacol. 2011, 62:349-380.
64. Mayr B., Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2001, 2:599-609.
65. McNamee E.N., Griffin E.W., Ryan K.M., Ryan K.J., Heffernan S., Harkin A., Connor T.J. Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. Neuropharmacology 2010, 59:37-48.
66. Miller G.E., Chen E., Sze J., Marin T., Arevalo J.M., Doll R., Ma R., Cole S.W. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 2008, 64:266-272.
67. Moon E.Y., Lee J.H., Lee J.W., Song J.H., Pyo S. ROS/Epac1-mediated Rap1/NF-kappaB activation is required for the expression of BAFF in Raw264.7 murine macrophages. Cell. Signal. 2011, 23:1479-1488.
68. Mortaz E., Rad M.V., Johnson M., Raats D., Nijkamp F.P., Folkerts G. Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J. Mol. Med. (Berl.) 2008, 86:1045-1056.
69. Nakamura A., Johns E.J., Imaizumi A., Yanagawa Y., Kohsaka T. Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription. J. Am. Soc. Nephrol. 2001, 12:2288-2299.
70. Natoli G., Saccani S., Bosisio D., Marazzi I. Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat. Immunol. 2005, 6:439-445.
71. Neumann M., Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J. 2007, 21:2642-2654.
72. Neves S.R., Ram P.T., Iyengar R. G protein pathways. Science 2002, 296:1636-1639.
73. Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. J. Biol. Chem. 2005, 280:2550-2561.
74. O'Sullivan J.B., Ryan K.M., Curtin N.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int. J. Neuropsychopharmacol. 2009, 12:687-699.
75. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 2011, 12:695-708.
76. Oldenburger A., Roscioni S.S., Jansen E., Menzen M.H., Halayko A.J., Timens W., Meurs H., Maarsingh H., Schmidt M. Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PLoS ONE 2012, 7:e31574.
77. Padro C.J., Sanders V.M. Neuroendocrine regulation of inflammation. Semin. Immunol. 2014, 10.1016/j.smim.2014.01.003.
78. Parry G.C., Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J. Immunol. 1997, 159:5450-5456.
79. Perkins N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25:6717-6730.
80. Philipp M., Hein L. Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol. Ther. 2004, 101:65-74.
81. Powell N.D., Tarr A.J., Sheridan J.F. Psychosocial stress and inflammation in cancer. Brain Behav. Immun. 2013, 30(Suppl.):S41-7.
82. Pullar C.E., Rizzo A., Isseroff R.R. Beta-adrenergic receptor antagonists accelerate skin wound healing: evidence for a catecholamine synthesis network in the epidermis. J. Biol. Chem. 2006, 281:21225-21235.
83. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
84. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2002, 2:664-674.
85. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318:1266-1273.
86. Ryan K.J., Griffin E., Yssel J.D., Ryan K.M., McNamee E.N., Harkin A., Connor T.J. Stimulation of central beta2-adrenoceptors suppresses NFkappaB activity in rat brain: a role for IkappaB. Neurochem. Int. 2013, 63:368-378.
87. Sanders V.M. The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet?. Brain Behav. Immun. 2012, 26:195-200.
88. Shenoy S.K., Lefkowitz R.J. Beta-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 2011, 32:521-533.
89. Singh H., Sen R., Baltimore D., Sharp P.A. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 1986, 319:154-158.
90. Smale S.T. Hierarchies of NF-kappaB target-gene regulation. Nat. Immunol. 2011, 12:689-694.
91. Spooren A., Kolmus K., Vermeulen L., Van Wesemael K., Haegeman G., Gerlo S. Hunting for serine 276-phosphorylated p65. J. Biomed. Biotechnol. 2010, 2010:275892.
92. Spooren A., Kooijman R., Lintermans B., Van Craenenbroeck K., Vermeulen L., Haegeman G., Gerlo S. Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in astrocytes. Cell. Signal. 2010, 22:871-881.
93. Spooren A., Mestdagh P., Rondou P., Kolmus K., Haegeman G., Gerlo S. IL-1beta potently stabilizes IL-6 mRNA in human astrocytes. Biochem. Pharmacol. 2011, 81:1004-1015.
94. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 2006, 6:318-328.
95. Strell C., Sievers A., Bastian P., Lang K., Niggemann B., Zanker K.S., Entschladen F. Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes. BMC Immunol. 2009, 10:62.
96. Taniguchi K., Karin M. IL-6 and released cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 2014, 26:54-74.
97. Thanawala V.J., Forkuo G.S., Stallaert W., Leff P., Bouvier M., Bond R. Ligand bias prevents class equality among beta-blockers. Curr. Opin. Pharmacol. 2014, 16C:50-57.
98. Theron A.J., Steel H.C., Tintinger G.R., Feldman C., Anderson R. Can the anti-inflammatory activities of beta2-agonists be harnessed in the clinical setting?. Drug Des. Dev. Ther. 2013, 7:1387-1398.
99. van der Westhuizen E.T., Breton B., Christopoulos A., Bouvier M. Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy. Mol. Pharmacol. 2014, 85:492-509.
100. Vanden Berghe W., De Bosscher K., Boone E., Plaisance S., Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J. Biol. Chem. 1999, 274:32091-32098.
101. Vanden Berghe W., Ndlovu M.N., Hoya-Arias R., Dijsselbloem N., Gerlo S., Haegeman G. Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem. Pharmacol. 2006, 72:1114-1131.
102. 2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS ONE 2013, 8:e56058.
103. Walsh D.A., Perkins J.P., Krebs E.G. An adenosine 3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. J. Biol. Chem. 1968, 243:3763-3765.
104. Wang W., Xu M., Zhang Y.Y., He B. Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line. Acta Pharmacol. Sin. 2009, 30:1522-1528.
105. White R.E., Palm C., Xu L., Ling E., Ginsburg M., Daigle B.J., Han R., Patterson A., Altman R.B., Giffard R.G. Mice lacking the beta2 adrenergic receptor have a unique genetic profile before and after focal brain ischaemia. ASN Neuro 2012, 4. art:e00096. 10.1042/AN2011.
106. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., Shenoy S.K., Lefkowitz R.J. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 2007, 204:16657-16662.
107. Witherow D.S., Garrison T.R., Miller W.E., Lefkowitz R.J. Beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8603-8607.
108. Xiao R.P., Ji X., Lakatta E.G. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 1995, 47:322-329.
109. Yamaya M., Nishimura H., Nadine L., Kubo H., Ryoichi. Tulobuterol inhibits Rhinovirus infection in primary cultures of human tracheal epithelial cells. Physiol. Rep. 2013, 1:e00041.
110. Yang S.P., Ho L.J., Lin Y.L., Cheng S.M., Tsao T.P., Chang D.M., Hsu Y.L., Shih C.Y., Juan T.Y., Lai J.H. Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity. Cardiovasc. Res. 2003, 59:776-787.
111. Yang Y., Shi Q., Liu Z., Li R.J., Pan P.W., Hou Y.Y., Lu W.G., Bai G. The synergistic anti-asthmatic effects of glycyrrhizin and salbutamol. Acta Pharmacol. Sin. 2010, 31:443-449.
112. Yano N., Ianus V., Zhao T.C., Tseng A., Padbury J.F., Tseng Y.T. A novel signaling pathway for beta-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H385-H393.
113. Yeh C.K., Chandrasekar B., Lin A.L., Dang H., Kamat A., Zhu B., Katz M.S. Cellular signals underlying beta-adrenergic receptor mediated salivary gland enlargement. Differentiation 2012, 83:68-76.
114. Yin F., Wang Y.Y., Du J.H., Li C., Lu Z.Z., Han C., Zhang Y.Y. Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J. Mol. Cell. Cardiol. 2006, 40:384-393.
115. Yoon C., Korade Z., Carter B.D. Protein kinase A-induced phosphorylation of the p65 subunit of nuclear factor-kappaB promotes Schwann cell differentiation into a myelinating phenotype. J. Neurosci. 2008, 28:3738-3746.
116. Zheng M., Zhang S.J., Zhu W.Z., Ziman B., Kobilka B.K., Xiao R.P. Beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes. J. Biol. Chem. 2000, 275:40635-40640.
117. Zhong H., SuYang H., Erdjument-Bromage H., Tempst P., Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997, 89:413-424.
118. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1998, 1:661-671.